# Study of ZG006 in Participants With Neuroendocrine Prostate Cancer

> **NCT07024277** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 60 (estimated)

## Conditions studied

- Neuroendocrine Prostate Cancer

## Interventions

- **BIOLOGICAL:** ZG006

## Key facts

- **NCT ID:** NCT07024277
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07024277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07024277, "Study of ZG006 in Participants With Neuroendocrine Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07024277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*